“Oral medications would be much cheaper for patients and I think would make less money for the companies making it,” said Shauna Levy, an obesity medicine specialist at Tulane University School of Medicine. She added that companies have already “proven they can make an effective” oral version of GLP-1 medications. “I think this is one of the main reasons they are not currently pushing for oral semaglutide and saving all the semaglutide of injectable medication.”